Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit Beuselinck

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
European Urology|December 20, 2014
Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapiesNils Kroeger, Allan J Pantuck, J Connor Wells, et al.
JAMA Network Open|January 21, 2021
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With SurvivalShaan Dudani, Guillermo de Velasco, J Connor Wells, et al.
European Urology|October 25, 2016
Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic CategoryIan D Davis, Wanling Xie, Carmel Pezaro, et al.
Clinical Genitourinary Cancer|August 9, 2022
CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)Vishal Navani, J Connor Wells, Devon J Boyne, et al.
Nature Medicine|May 21, 2024
A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinomaLisa Kinget, Stefan Naulaerts, Jannes Govaerts, et al.
The Journal of Urology|December 27, 2022
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Vishal Navani, Matthew S Ernst, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2022
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapyJeffrey Graham, John Connor Wells, Shaan Dudani, et al.
JCI Insight|October 5, 2016
Deep sequencing reveals microRNAs predictive of antiangiogenic drug responseJesús García-Donas, Benoit Beuselinck, Lucía Inglada-Pérez, et al.
Clinical Genitourinary Cancer|October 14, 2025
CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)Audreylie Lemelin, David Maj, Kosuke Takemura, et al.
Cancer Medicine|January 19, 2021
Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumChun Loo Gan, Shaan Dudani, J Connor Wells, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
European Urology|December 20, 2014
Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapiesNils Kroeger, Allan J Pantuck, J Connor Wells, et al.
JAMA Network Open|January 21, 2021
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With SurvivalShaan Dudani, Guillermo de Velasco, J Connor Wells, et al.
European Urology|October 25, 2016
Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic CategoryIan D Davis, Wanling Xie, Carmel Pezaro, et al.
Clinical Genitourinary Cancer|August 9, 2022
CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)Vishal Navani, J Connor Wells, Devon J Boyne, et al.
Nature Medicine|May 21, 2024
A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinomaLisa Kinget, Stefan Naulaerts, Jannes Govaerts, et al.
The Journal of Urology|December 27, 2022
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Vishal Navani, Matthew S Ernst, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2022
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapyJeffrey Graham, John Connor Wells, Shaan Dudani, et al.
JCI Insight|October 5, 2016
Deep sequencing reveals microRNAs predictive of antiangiogenic drug responseJesús García-Donas, Benoit Beuselinck, Lucía Inglada-Pérez, et al.
Clinical Genitourinary Cancer|October 14, 2025
CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)Audreylie Lemelin, David Maj, Kosuke Takemura, et al.
Cancer Medicine|January 19, 2021
Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumChun Loo Gan, Shaan Dudani, J Connor Wells, et al.
Pageof 12